Navigation Links
New Report Analyzes Key Controversies in Multiple Sclerosis Treatment
Date:11/14/2007

SCOTTSDALE, Ariz., Nov. 14 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for MS therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Multiple Sclerosis," physician experts discuss the key controversies emerging from ECTRIMS (European Committee for Treatment and Research in MS) 2007, including:

-- Early aggressive therapy vs. more conservative approaches.

-- The negative results from REGARD, and implications for the powering of

MS trials. The report offers predictions on results expected in the

BEYOND, PreCISe and OLYMPUS.

-- The potential for pulmonary delivery of interferon and Copaxone.

-- The numerous orally available drugs in development for MS. The report

reviews the benefits and drawbacks of fingolimod, other S1Ps,

short-acting VLA4, teriflunomide, laquinimod, fampridine, fumarates and

other oral options, and predicts where they will fall on the

safety/efficacy spectrum.

-- The status and potential of a number of vaccine approaches.

-- Intriguing neuroprotection / neuroregeneration strategies, including

LINGO, anti-myelin-associated-glycoprotein MAb and remyelination MAb.

Drugs/Mechanisms mentioned in this report include: S1P agonists (fingolimod; Novartis, S1P1; Roche/Actelion, Sphingomab; Lpath, S1P1 modulators; Epix / Amgen), inhibitors of DNA synthesis/repair (teriflunomide; Sanofi-Aventis, cladribine; Ivax/Serono), potassium channel blockers (fampridine; Acorda, BNC-245; Bionomics), interferons (Avonex; Biogen, Rebif; Ares-Serono, Betaseron; Bayer-Schering and Biferonex; Biopartners Holdings), VLA4 inhibitors (Tysabri; Biogen/Elan, firategrast; GlaxoSmithKline, CDP-323; UCB/Biogen; ATL1102 (Antisense Th
'/>"/>

SOURCE MedPredict Market Research
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... FL (PRWEB) May 26, 2015 ... Inc. have announced plans for the company’s first cellular ... 2015, followed by a full day, hands-on stem cell ... by J. Victor Garcia Gimenez, M.D., President of Therapeutic ... the medical community’s increasing interest in regenerative medicine and ...
(Date:5/26/2015)...  A simple blood test developed at the University ... Alzheimer,s disease is a step closer to being used ... that are needed before a blood test could be ... & Dementia . The guidelines establish protocols and reflect ... includes UNT Health Science Center. "If we ...
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... company,s Phase IIb trial of ORMD-0801, its oral insulin ... The submission was made under the company,s existing Investigational ... study of ORMD-0801 for type 2 diabetics is designed ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... the leading online,information source for life science ... launched the 2nd Edition of the Southern ... science community of the Southeastern,United States. The ... that constitute the dynamic biopharmaceutical industry in ...
... Celgosivir 4-Week Viral Kinetics Study Data on ... Monday December 3, ... Inc.,(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results ...
... NOLabs AB, the Swedish,medtech company developing innovative ... Technology, today reported that it has,achieved another ... new line of,products for wounds infected by ... a bacterium that is particularly,troublesome in hospital-acquired ...
Cached Biology Technology:BioSpace Launches 2nd Edition of Southern Pharm(TM) Hotbed Campaign 2MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria 2
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... stem cell research journals? This question has been ... Department of Neurosurgery and Brain Repair at the University of ... Stem Cell Reviews and Reports . Both Sanberg ... being published in the proliferating stem cell journals. ...
... herd of cattle is more than just cows. It,s a ... and hedge against drought. For many smallholder farmers, the loss ... Yet a grievous number of cattle in sub-Saharan Africa ... $40 billion, some twenty-five percent of the total value of ...
... Spring Harbor, NY -- One of the most tantalizing developments ... of targeted treatments, which have proven highly effective in holding ... for a limited period of time. A team led ... Harbor Laboratory (CSHL), today published results of a study that ...
Cached Biology News:Cow vaccines go vroom 2Cow vaccines go vroom 3New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered 2
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: